Sandbox ID Genitourinary: Difference between revisions

Jump to navigation Jump to search
Line 4: Line 4:
* '''Chancroid'''<ref>{{Cite journal| issn = 1545-8601| volume = 59| issue = RR-12| pages = 1–110| last1 = Workowski| first1 = Kimberly A.| last2 = Berman| first2 = Stuart| last3 = Centers for Disease Control and Prevention (CDC)| title = Sexually transmitted diseases treatment guidelines, 2010| journal = MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control| date = 2010-12-17| pmid = 21160459}}</ref>
* '''Chancroid'''<ref>{{Cite journal| issn = 1545-8601| volume = 59| issue = RR-12| pages = 1–110| last1 = Workowski| first1 = Kimberly A.| last2 = Berman| first2 = Stuart| last3 = Centers for Disease Control and Prevention (CDC)| title = Sexually transmitted diseases treatment guidelines, 2010| journal = MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control| date = 2010-12-17| pmid = 21160459}}</ref>
:* Preferred regimen: [[Azithromycin]] 1 g PO in a single dose {{or}} [[Ceftriaxone]] 250 mg IM in a single dose {{or}} [[Ciprofloxacin]] 500 mg PO bid for 3 days {{or}} [[Erythromycin]] 500 mg PO tid for 7 days
:* Preferred regimen: [[Azithromycin]] 1 g PO in a single dose {{or}} [[Ceftriaxone]] 250 mg IM in a single dose {{or}} [[Ciprofloxacin]] 500 mg PO bid for 3 days {{or}} [[Erythromycin]] 500 mg PO tid for 7 days
:* Ciprofloxacin is contraindicated for pregnant and lactating women.
:: Note: Ciprofloxacin is contraindicated for pregnant and lactating women.


----
----

Revision as of 07:58, 28 May 2015

Chancroid

Note: Ciprofloxacin is contraindicated for pregnant and lactating women.

Gonococcal infection

  • Gonococcal infection[2]Centers for Disease Control and Prevention (CDC) (2012-08-10). "Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections". MMWR. Morbidity and mortality weekly report. 61 (31): 590–594. ISSN 1545-861X. PMID 22874837.</ref>
  • Uncomplicated Gonococcal Infections of the Cervix, Urethra, and Rectum
  • Uncomplicated Gonococcal Infections of the Pharynx
  • Gonococcal Conjunctivitis
  • Disseminated Gonococcal Infection (DGI)
Note: All of the preceding regimens should be continued for 24-48 hours after improvement begins, at which time therapy can be switched to Cefixime 400 mg PO bid to complete at least 1 week of antimicrobial therapy.
  • Gonococcal Meningitis
  • Preferred regimen: Ceftriaxone 1-2 g IV every 12 hours for 10-14 days
  • Gonococcal Endocarditis
  • Preferred regimen: Ceftriaxone 1-2 g IV every 12 hours for at least 4 weeks
  • Gonococcal Infections Among Infants
  • Ophthalmia Neonatorum Caused by N. gonorrhoeae
  • Preferred regimen: Ceftriaxone 25-50 mg/kg IV or IM in a single dose, not to exceed 125 mg
  • DGI and Gonococcal Scalp Abscesses in Newborns
  • Preferred regimen:



Workowski, Kimberly A.; Berman, Stuart; Centers for Disease Control and Prevention (CDC) (2010-12-17). "Sexually transmitted diseases treatment guidelines, 2010". MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 59 (RR-12): 1–110. ISSN 1545-8601. PMID 21160459.




References

  1. Workowski, Kimberly A.; Berman, Stuart; Centers for Disease Control and Prevention (CDC) (2010-12-17). "Sexually transmitted diseases treatment guidelines, 2010". MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 59 (RR-12): 1–110. ISSN 1545-8601. PMID 21160459.
  2. Workowski, Kimberly A.; Berman, Stuart; Centers for Disease Control and Prevention (CDC) (2010-12-17). "Sexually transmitted diseases treatment guidelines, 2010". MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 59 (RR-12): 1–110. ISSN 1545-8601. PMID 21160459.